KPV (Ac-KPV-NH2) 10 mg

Description

KPV (Ac-KPV-NH2) is a synthetic tripeptide corresponding to the
C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). In experimental models
it modulates inflammatory signalling through melanocortin receptor activation and NF-κB
pathway inhibition. It is used in research investigating epithelial integrity, cytokine balance
and immune-mediated stress responses.

What is KPV?

Ac-KPV-NH2 is one of a number of short α-MSH-derived fragments examined to establish
which activities of the parent hormone they retain. Composed of lysine-proline-valine, it is
reported to retain substantial anti-inflammatory activity in models of the central nervous
system, gastrointestinal tract, lung, vasculature and joints, without the melanocortin-mediated
effects of full-length α-MSH.

The sections below summarise findings reported in published preclinical and early-stage literature. They describe what has been observed in study models, not outcomes offered to any purchaser.

Areas of Research Interest

1. Inflammatory signalling

• Inhibition of NF-κB, a principal inflammatory signalling pathway
• Reduction of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)
• Behaviour in models of chronic inflammatory activation

Model systems in the published literature include inflammatory bowel disease, colitis,
cutaneous inflammation and autoimmune inflammation.

2. Epithelial barrier models

• Intestinal barrier integrity and tight-junction function
• Epithelial permeability in colitis models
• Mucosal repair signalling

The literature frequently examines KPV alongside BPC-157, as the two are studied for different
mechanisms — inflammatory signalling versus tissue-repair signalling.

3. Immune modulation rather than suppression

• Normalisation of overactive immune signalling in study models
• Retention of host-defence capability
• Cytokine balance where immune regulation is disrupted

4. Dermatological models

• Markers of cutaneous inflammation and erythema
• Models of eczema, psoriasis and dermatitis
• Both topical and systemic research preparations

5. Antimicrobial activity

• Inhibition of certain pathogenic bacteria in vitro
• Indirect effects on microbiome composition through reduced inflammation

6. Tolerability in the published record

In research settings KPV is reported to show low toxicity, good tolerability, and none of the
hormonal or melanocortin-related effects associated with full α-MSH. It is not anabolic and
is not reported to act on hormonal or analgesic pathways directly.

References

• Getting SJ et al., J Immunol, 1999;163(10):5959–5967
• Lipton JM et al., Ann NY Acad Sci, 2009;1170:123–130
• Grieco P et al., Peptides, 2013;44:111–115

Handling and Storage

Lyophilised powder. Store the sealed vial refrigerated and protected from light. To be handled
only by trained laboratory personnel in an appropriate research setting.

Research Use Only
This product is sold exclusively as a research chemical for in-vitro laboratory investigation by qualified researchers. It is not a drug, not a dietary supplement, and not intended for human or veterinary consumption, diagnostic use, or any form of therapeutic application. No statement on this page should be read as medical advice or as a claim that this compound treats, prevents, or cures any condition. Findings referenced above are drawn from published preclinical and clinical literature and are provided for scientific reference only.